No Data
Kangchen Pharmaceutical\'s 2024 Third Quarter Report
Beijing Konruns Pharmaceutical (603590.SH): The net income in the first three quarters is approximately 0.113 billion yuan, a decrease of 23.99% year-on-year.
Kang Chen Pharmaceuticals (603590.SH) announced on October 29th that its revenue for the first three quarters of 2024 was approximately 0.646 billion yuan, a decrease of 10.24% year-on-year; net income attributable to shareholders of the listed company was approximately 0.113 billion yuan, a decrease of 23.99% year-on-year; and the basic earnings per share was 0.7189 yuan.
Beijing Konruns Pharmaceutical (603590.SH): The late-stage esophageal squamous cell carcinoma stage III clinical study KC1036 is being conducted in an orderly manner according to plan.
Oct. 8th, Kangchen Pharmaceutical (603590.SH) stated during a specific research interview that KC1036 has made breakthroughs in clinical diversification, entering late-stage clinical research for stage Ⅲ esophageal squamous cell carcinoma. KC1036 is a multi-target receptor tyrosine kinase inhibitor independently developed by the company, and is systematically conducting multiple clinical trials as planned, with a focus on treating late-stage esophageal squamous cell carcinoma in clinical research for stage Ⅲ, maintaining local late-stage or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with PD-1 antibodies, and treating late-stage EWING sarcoma in adolescents aged 12 and above.
Kangchen Pharmaceutical 2024 Semi-Annual Report
Summary of Kangchen Pharmaceutical\'s 2024 Semi-Annual Report
Beijing Konruns Pharmaceutical (603590.SH) released its performance for the first half of the year, with a net income of 79.2028 million yuan, a decrease of 14.73% compared to the same period last year.
Beijing Konruns Pharmaceutical (603590.SH) released its 2024 interim report, with the company achieving revenue of 4...
